We are analyzing https://link.springer.com/article/10.1007/s11906-011-0207-x.

Title:
Effects of Antihypertensive Treatment on Endothelial Function | Current Hypertension Reports
Description:
Essential hypertension is characterized by endothelial dysfunction due to reduced availability of nitric oxide (NO) secondary to increased generation of oxygen-free radicals. Some antihypertensive drugs may improve or restore endothelial function independently of their blood pressure lowering effect. The newer generation of β-blockers, such as nebivolol and carvedilol, which provide antioxidant activity, can improve endothelial function in patients with hypertension. Dihydropyridine and non-dihydropyridine calcium antagonists reverse impaired endothelium-dependent vasodilatation in different vascular districts, through a mechanism related to an antioxidant effect. However, conflicting results are found in the brachial artery. Angiotensin-converting enzyme (ACE) inhibitors improve endothelial function in subcutaneous, epicardial, brachial, and renal circulation, but they are ineffective in potentiating the impaired response to acetylcholine in the forearm of hypertensive patients. Angiotensin II receptor antagonists can restore endothelium-dependent vasodilatation to acetylcholine in subcutaneous microcirculation but not in that of the forearm muscle. They also improve basal NO release and decrease the vasoconstrictor effect of endogenous endothelin-1. Large-scale clinical trials are required to definitively demonstrate that treatment of endothelial dysfunction can improve the prognosis of patients with essential hypertension.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

google, scholar, pubmed, cas, article, hypertension, endothelial, patients, function, essential, virdis, ghiadoni, effect, hypertensive, taddei, treatment, dysfunction, artery, coronary, calcium, circulation, effects, antihypertensive, angiotensin, nitric, vasodilation, hypertens, study, oxide, improves, endotheliumdependent, vascular, arteries, enzyme, receptor, antagonist, inhibition, privacy, cookies, content, drugs, improve, antioxidant, antagonists, brachial, access, structure, channel, nifedipine, disease,

Topics {✒️}

angiotensin-converting enzyme inhibitors oral renin inhibitors restore endothelium-dependent vasodilatation endothelial-dependent flow-mediated vasodilation calcium channel blockers angiotensin ii-infused mice improves endothelium-dependent vasodilation angiotensin-converting enzyme inhibition endothelium-dependent vasodilatation month download article/chapter calcium antagonists nitric oxide-dependent vasodilation angiotensin ii antagonism calcium channel antagonist lorenzo ghiadoni & stefano taddei angiotensin-converting enzyme calcium channel blockade noninsulin-dependent diabetes mellitus flow-dependent vasodilation large-scale clinical trials flow-mediated vasodilation improves endothelial dysfunction long-term antihypertensive treatment beta blockade treatment randomized placebo-controlled study full article pdf nitric oxide availability beta-blocker β-blockers calcium antagonist treatment abnormal coronary vasomotion endothelial nitric oxide privacy choices/manage cookies endothelial dysfunction due reversing endothelial dysfunction ruffolo jr rr ace-inhibition ace inhibition check access instant access beta-blockade human essential hypertension encore ii study related subjects lercanidipine prevents hyperpolarization calcium antagonist coronary endothelial function ameliorate endothelial function coronary artery disease european economic area

Questions {❓}

Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effects of Antihypertensive Treatment on Endothelial Function
         description:Essential hypertension is characterized by endothelial dysfunction due to reduced availability of nitric oxide (NO) secondary to increased generation of oxygen-free radicals. Some antihypertensive drugs may improve or restore endothelial function independently of their blood pressure lowering effect. The newer generation of β-blockers, such as nebivolol and carvedilol, which provide antioxidant activity, can improve endothelial function in patients with hypertension. Dihydropyridine and non-dihydropyridine calcium antagonists reverse impaired endothelium-dependent vasodilatation in different vascular districts, through a mechanism related to an antioxidant effect. However, conflicting results are found in the brachial artery. Angiotensin-converting enzyme (ACE) inhibitors improve endothelial function in subcutaneous, epicardial, brachial, and renal circulation, but they are ineffective in potentiating the impaired response to acetylcholine in the forearm of hypertensive patients. Angiotensin II receptor antagonists can restore endothelium-dependent vasodilatation to acetylcholine in subcutaneous microcirculation but not in that of the forearm muscle. They also improve basal NO release and decrease the vasoconstrictor effect of endogenous endothelin-1. Large-scale clinical trials are required to definitively demonstrate that treatment of endothelial dysfunction can improve the prognosis of patients with essential hypertension.
         datePublished:2011-04-16T00:00:00Z
         dateModified:2011-04-16T00:00:00Z
         pageStart:276
         pageEnd:281
         sameAs:https://doi.org/10.1007/s11906-011-0207-x
         keywords:
            Essential hypertension
            High blood pressure
            Endothelial dysfunction
            Beta-blockers
            Calcium channel antagonists
            ACE inhibitors
            Angiotensin II receptor antagonists
            Vasodilatation
            Renin-angiotensin system
            Internal Medicine
            Cardiology
            Metabolic Diseases
            Nephrology
            Primary Care Medicine
            General Practice / Family Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11906-011-0207-x/MediaObjects/11906_2011_207_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11906-011-0207-x/MediaObjects/11906_2011_207_Fig2_HTML.gif
         isPartOf:
            name:Current Hypertension Reports
            issn:
               1534-3111
               1522-6417
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Current Science Inc.
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Agostino Virdis
               affiliation:
                     name:University of Pisa
                     address:
                        name:Department of Internal Medicine, University of Pisa, Pisa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lorenzo Ghiadoni
               affiliation:
                     name:University of Pisa
                     address:
                        name:Department of Internal Medicine, University of Pisa, Pisa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stefano Taddei
               affiliation:
                     name:University of Pisa
                     address:
                        name:Department of Internal Medicine, University of Pisa, Pisa, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effects of Antihypertensive Treatment on Endothelial Function
      description:Essential hypertension is characterized by endothelial dysfunction due to reduced availability of nitric oxide (NO) secondary to increased generation of oxygen-free radicals. Some antihypertensive drugs may improve or restore endothelial function independently of their blood pressure lowering effect. The newer generation of β-blockers, such as nebivolol and carvedilol, which provide antioxidant activity, can improve endothelial function in patients with hypertension. Dihydropyridine and non-dihydropyridine calcium antagonists reverse impaired endothelium-dependent vasodilatation in different vascular districts, through a mechanism related to an antioxidant effect. However, conflicting results are found in the brachial artery. Angiotensin-converting enzyme (ACE) inhibitors improve endothelial function in subcutaneous, epicardial, brachial, and renal circulation, but they are ineffective in potentiating the impaired response to acetylcholine in the forearm of hypertensive patients. Angiotensin II receptor antagonists can restore endothelium-dependent vasodilatation to acetylcholine in subcutaneous microcirculation but not in that of the forearm muscle. They also improve basal NO release and decrease the vasoconstrictor effect of endogenous endothelin-1. Large-scale clinical trials are required to definitively demonstrate that treatment of endothelial dysfunction can improve the prognosis of patients with essential hypertension.
      datePublished:2011-04-16T00:00:00Z
      dateModified:2011-04-16T00:00:00Z
      pageStart:276
      pageEnd:281
      sameAs:https://doi.org/10.1007/s11906-011-0207-x
      keywords:
         Essential hypertension
         High blood pressure
         Endothelial dysfunction
         Beta-blockers
         Calcium channel antagonists
         ACE inhibitors
         Angiotensin II receptor antagonists
         Vasodilatation
         Renin-angiotensin system
         Internal Medicine
         Cardiology
         Metabolic Diseases
         Nephrology
         Primary Care Medicine
         General Practice / Family Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11906-011-0207-x/MediaObjects/11906_2011_207_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11906-011-0207-x/MediaObjects/11906_2011_207_Fig2_HTML.gif
      isPartOf:
         name:Current Hypertension Reports
         issn:
            1534-3111
            1522-6417
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Current Science Inc.
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Agostino Virdis
            affiliation:
                  name:University of Pisa
                  address:
                     name:Department of Internal Medicine, University of Pisa, Pisa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lorenzo Ghiadoni
            affiliation:
                  name:University of Pisa
                  address:
                     name:Department of Internal Medicine, University of Pisa, Pisa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stefano Taddei
            affiliation:
                  name:University of Pisa
                  address:
                     name:Department of Internal Medicine, University of Pisa, Pisa, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Hypertension Reports
      issn:
         1534-3111
         1522-6417
      volumeNumber:13
Organization:
      name:Current Science Inc.
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Pisa
      address:
         name:Department of Internal Medicine, University of Pisa, Pisa, Italy
         type:PostalAddress
      name:University of Pisa
      address:
         name:Department of Internal Medicine, University of Pisa, Pisa, Italy
         type:PostalAddress
      name:University of Pisa
      address:
         name:Department of Internal Medicine, University of Pisa, Pisa, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Agostino Virdis
      affiliation:
            name:University of Pisa
            address:
               name:Department of Internal Medicine, University of Pisa, Pisa, Italy
               type:PostalAddress
            type:Organization
      name:Lorenzo Ghiadoni
      affiliation:
            name:University of Pisa
            address:
               name:Department of Internal Medicine, University of Pisa, Pisa, Italy
               type:PostalAddress
            type:Organization
      name:Stefano Taddei
      affiliation:
            name:University of Pisa
            address:
               name:Department of Internal Medicine, University of Pisa, Pisa, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Internal Medicine, University of Pisa, Pisa, Italy
      name:Department of Internal Medicine, University of Pisa, Pisa, Italy
      name:Department of Internal Medicine, University of Pisa, Pisa, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(156)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.24s.

LINK . SPRINGER . COM {}